These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19643598)

  • 1. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
    Okines A; Cunningham D
    Eur J Cancer; 2009 Sep; 45(14):2452-61. PubMed ID: 19643598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
    Grothey A; Hedrick EE; Mass RD; Sarkar S; Suzuki S; Ramanathan RK; Hurwitz HI; Goldberg RM; Sargent DJ
    J Clin Oncol; 2008 Jan; 26(2):183-9. PubMed ID: 18182660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H; Kabbinavar F
    Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future development of bevacizumab in colorectal cancer.
    Díaz-Rubio E; Schmoll HJ
    Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
    Vaidyanathan G; Groman A; Wilding G; Fakih MG
    Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
    Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V; Hoff PM
    Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
    Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
    Kabbinavar F; Irl C; Zurlo A; Hurwitz H
    Oncology; 2008; 75(3-4):215-23. PubMed ID: 18852492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.